As anticipated, we therefore more recently found that mirabegron does not accelerate atherosclerosis development in APOE*3-Leiden.CETP mice, due to effective removal of VLDL remnants via the intact ApoE–LDLR pathway (104). Here, LDLR is linked to atherosclerosis.